Corcept Therapeutics Inc (CORT)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$37.77
Buy
$43.73
$0.51 (+1.21%)
Prices updated at 03 Apr 2026, 00:58 EDT
| Prices minimum 15 mins delay
Prices in USD
Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. James N. Wilson
CEO
Dr. Joseph K. Belanoff, M.D.
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
730
Head office
101 Redwood Shores Parkway
Redwood City
United States
94065
Key personnel
Owner name | Salary |
|---|---|
Mr. David L. Mahoney Independent Director | 0.08m |
Mr. Daniel N. Swisher,Jr Independent Director | 0.06m |
Mr. George Leonard Baker, Jr Independent Director | 0.07m |
Dr. Gregg H. Alton, J.D. Independent Director | 0.09m |
Dr. Joseph K. Belanoff, M.D. Director, President and Chief Executive Officer | 1.14m |
Mr. James N. Wilson Chairman of the Board | 0.13m |
Mr. Atabak Mokari Chief Financial Officer and Treasurer | 0.55m |
Ms. Kimberly Park Independent Director | 0.06m |
Mr. Joseph Douglas Lyon Chief Accounting Officer and Chief Technology Officer | - |
Mr. Joshua M. Murray Independent Director | 0.06m |
Mr. G. Charles Robb Chief Business Officer and Secretary | 0.69m |
Mr. Sean Maduck President, Corcept Endocrinology | 0.63m |
Dr. Hazel Hunt, PhD Chief Scientific Officer | - |
Dr. William Guyer, Pharm.D. Chief Development Officer | 0.66m |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| BlackRock Inc | 12,047,830 |
| Vanguard Group Inc | 9,494,822 |
| BlackRock Fund Advisors | 8,571,538 |
| Ingalls & Snyder LLC | 7,195,060 |
| Renaissance Technologies Corp | 5,758,528 |
Director dealings
Date | Action |
|---|---|
| 24 Dec 2025 | - |
| 24 Dec 2025 | - |
| 24 Dec 2025 | - |
| 24 Dec 2025 | - |
| 24 Dec 2025 | - |
| 24 Dec 2025 | - |
| 24 Dec 2025 | - |
| 24 Dec 2025 | - |
| 12 Dec 2025 | - |
| 12 Dec 2025 | - |
| 12 Dec 2025 | - |
| 01 Dec 2025 | - |
| 01 Dec 2025 | - |
| 01 Dec 2025 | - |
| 02 Dec 2025 | - |
| 01 Dec 2025 | - |
| 02 Dec 2025 | - |
| 01 Dec 2025 | - |
| 01 Dec 2025 | - |
| 01 Dec 2025 | - |
Please note that past performance is not a reliable indicator of future returns.
